Insulin resistance implications for type II diabetes mellitus and coronary heart disease (Q41579716)

4 October 2017

1 reference

title

Insulin resistance implications for type II diabetes mellitus and coronary heart disease (English)

1 reference

4 October 2017

0 references

1 reference

1

Haffner SM

1 reference

4 October 2017

Miettinen H

2

1 reference

PubMed ID

9274899

4 October 2017

language of work or name

English

0 references

publication date

1 August 1997

1 reference

American Journal of Medicine

4 October 2017

1 reference

4 October 2017

103

1 reference

4 October 2017

152-162

1 reference

4 October 2017

2

1 reference

Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM.

4 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Banting lecture 1988. Role of insulin resistance in human disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Prospective analysis of the insulin-resistance syndrome (syndrome X).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

How good a marker is insulin level for insulin resistance?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Proinsulin and specific insulin concentration in high- and low-risk populations for NIDDM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Insulin resistance in essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Insulin and blood pressure: fact or fantasy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Essential hypertension and insulin resistance in non-insulin-dependent diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Racial differences in the relation between blood pressure and insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Insulin resistance and blood pressure in young black men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Clustering of cardiovascular risk factors in confirmed prehypertensive individuals.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Relationship between lipoprotein levels and in vivo insulin action in normal young white men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

A preponderance of small dense LDL is associated with specific insulin, proinsulin and the components of the insulin resistance syndrome in non-diabetic subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Coronary angioscopy in patients with unstable angina pectoris

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

The Prospective Cardiovascular Münster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Prevalence of small vessel and large vessel disease in diabetic patients from 14 centres. The World Health Organisation Multinational Study of Vascular Disease in Diabetics. Diabetes Drafting Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Type 2 (non-insulin-dependent) diabetes mellitus and coronary heart disease ? chicken, egg or neither?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Differences in cardiovascular morbidity and mortality between previously known and newly diagnosed adult diabetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

NIDDM and its metabolic control predict coronary heart disease in elderly subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Plasma insulin response among Nauruans. Prediction of deterioration in glucose tolerance over 6 yr

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Incidence of type II diabetes in Mexican Americans predicted by fasting insulin and glucose levels, obesity, and body-fat distribution.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Association of elevated fasting C-peptide level and increased intra-abdominal fat distribution with development of NIDDM in Japanese-American men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Risk factors for NIDDM in white population. Paris prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Cardiovascular disease risk factors as predictors of type 2 (non-insulin-dependent) diabetes mellitus in elderly subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Hyperglycemia and microvascular and macrovascular disease in diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Early atherosclerosis is retarded by improved long-term blood glucose control in patients with IDDM

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Relation of glycohemoglobin and adiposity to atherosclerosis in youth. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Cardiovascular disease risk factors prior to the diagnosis of impaired glucose tolerance and non-insulin-dependent diabetes mellitus in a community of older adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Do non-insulin-dependent diabetes mellitus and cardiovascular disease share common antecedents?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Coronary Heart Disease Incidence and Cardiovascular Mortality in Busselton with Reference to Glucose and Insulin Concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Hyperinsulinemia as an independent risk factor for ischemic heart disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Hyperinsulinemia does not increase the risk of fatal cardiovascular disease in elderly men or women without diabetes: the Rancho Bernardo Study, 1984-1991.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Insulin resistance and coronary artery disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Are insulin and proinsulin independent risk markers for premature coronary artery disease ?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Increased insulin resistance and insulin secretion in nondiabetic African-Americans and Hispanics compared with non-Hispanic whites. The Insulin Resistance Atherosclerosis Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Improvement of the plasma lipoprotein pattern after institution of insulin treatment in diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Effects of NIDDM on very-low-density lipoprotein triglyceride and apolipoprotein B metabolism. Studies before and after sulfonylurea therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

The feasibility of intensive insulin management in non-insulin-dependent diabetes mellitus. Implications of the Veterans Affairs Cooperative Study on Glycemic Control and Complications in NIDDM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Insulin and atheroma. 20-yr perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Implications of the Diabetes Control and Complications Trial. American Diabetes Association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Why is insulin not a risk factor for coronary heart disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Insulin resistance, compensatory hyperinsulinaemia, and coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Why can high insulin levels indicate a risk for coronary heart disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

The insulin resistance syndrome: the controversy is dead, long live the controversy!

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Insulin sensitivity and acute insulin response in African-Americans, non-Hispanic whites, and Hispanics with NIDDM: the Insulin Resistance Atherosclerosis Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Insulin-sensitive and insulin-resistant variants in NIDDM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Patterns of glucose and lipid abnormalities in black NIDDM subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Oral antidiabetic agents. The emergence of alpha-glucosidase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

7 January 2021

Sulfonylureas in NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

The pharmacological treatment of hyperglycemia in NIDDM. American Diabetes Association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Insulin resistance and the prevention of diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Diabetes and arterial hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Diabetes in hypertensive women: an effect of antihypertensive drugs or the hypertensive state per se?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Do antihypertensive drugs precipitate diabetes in predisposed men?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Incidence of NIDDM and impaired glucose tolerance in hypertensive subjects. The San Antonio Heart Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Effect of Antihypertensive Drugs on Insulin, Glucose, and Lipid Metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Antihypertensive drug therapy and the initiation of treatment for diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Insulin as a predictor of coronary heart disease: interaction with apolipoprotein E phenotype. A report from the Multiple Risk Factor Intervention Trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

Relation of fasting plasma insulin concentration to high density lipoprotein cholesterol and triglyceride concentrations in men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

inferred from DOI database lookup

7 January 2021

based on heuristic

Insulin sensitivity is not an independent determinant of plasma plasminogen activator inhibitor-1 activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900027-2

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(97)00027-2

1 reference

4 October 2017

1 reference

PubMed ID

9274899